1. Home
  2. EVAX vs MBIO Comparison

EVAX vs MBIO Comparison

Compare EVAX & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVAX
  • MBIO
  • Stock Information
  • Founded
  • EVAX 2008
  • MBIO 2015
  • Country
  • EVAX Denmark
  • MBIO United States
  • Employees
  • EVAX N/A
  • MBIO N/A
  • Industry
  • EVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • MBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVAX Health Care
  • MBIO Health Care
  • Exchange
  • EVAX Nasdaq
  • MBIO Nasdaq
  • Market Cap
  • EVAX 8.7M
  • MBIO 7.3M
  • IPO Year
  • EVAX 2021
  • MBIO N/A
  • Fundamental
  • Price
  • EVAX $2.49
  • MBIO $2.80
  • Analyst Decision
  • EVAX Strong Buy
  • MBIO Strong Buy
  • Analyst Count
  • EVAX 3
  • MBIO 1
  • Target Price
  • EVAX $33.33
  • MBIO $100.00
  • AVG Volume (30 Days)
  • EVAX 6.9M
  • MBIO 405.3K
  • Earning Date
  • EVAX 03-26-2025
  • MBIO 03-10-2025
  • Dividend Yield
  • EVAX N/A
  • MBIO N/A
  • EPS Growth
  • EVAX N/A
  • MBIO N/A
  • EPS
  • EVAX N/A
  • MBIO N/A
  • Revenue
  • EVAX $3,295,000.00
  • MBIO N/A
  • Revenue This Year
  • EVAX $9,039.73
  • MBIO N/A
  • Revenue Next Year
  • EVAX $1.47
  • MBIO N/A
  • P/E Ratio
  • EVAX N/A
  • MBIO N/A
  • Revenue Growth
  • EVAX N/A
  • MBIO N/A
  • 52 Week Low
  • EVAX $2.22
  • MBIO $2.40
  • 52 Week High
  • EVAX $22.50
  • MBIO $74.50
  • Technical
  • Relative Strength Index (RSI)
  • EVAX 39.85
  • MBIO 29.74
  • Support Level
  • EVAX $2.30
  • MBIO $2.40
  • Resistance Level
  • EVAX $2.80
  • MBIO $3.04
  • Average True Range (ATR)
  • EVAX 0.51
  • MBIO 0.65
  • MACD
  • EVAX 0.03
  • MBIO 0.06
  • Stochastic Oscillator
  • EVAX 6.97
  • MBIO 9.30

About EVAX Evaxion Biotech

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: